Pyxis Oncology Inc (PYXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -21,158 | -77,331 | -41,760 | -20,557 | -3,256 |
| Depreciation Amortization | -605 | -3,127 | -2,144 | -1,223 | -172 |
| Income taxes - deferred | N/A | -2,164 | N/A | N/A | N/A |
| Accounts receivable | N/A | N/A | N/A | N/A | -8,000 |
| Accounts payable and accrued liabilities | -2,013 | 1,200 | 1,210 | 1,812 | -1,365 |
| Other Working Capital | -4,596 | -9,659 | -5,164 | -9,463 | -21,766 |
| Other Operating Activity | 5,837 | 33,409 | 9,476 | 5,714 | 13,849 |
| Operating Cash Flow | $-22,535 | $-57,672 | $-38,382 | $-23,717 | $-20,710 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 15,821 | 8,392 | -18,265 | -18,257 | -18,261 |
| PPE Investments | N/A | -237 | -237 | -237 | -237 |
| Investing Cash Flow | $15,821 | $8,155 | $-18,502 | $-18,494 | $-18,498 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2 | 59,566 | 59,516 | 57,860 | 57,707 |
| Other Financing Activity | -2 | -240 | -240 | -239 | -196 |
| Financing Cash Flow | $0 | $59,326 | $59,276 | $57,621 | $57,511 |
| Beginning Cash Position | 20,945 | 11,136 | 11,136 | 11,136 | 11,136 |
| End Cash Position | 14,231 | 20,945 | 13,528 | 26,546 | 29,439 |
| Net Cash Flow | $-6,714 | $9,809 | $2,392 | $15,410 | $18,303 |
| Free Cash Flow | |||||
| Operating Cash Flow | -22,535 | -57,672 | -38,382 | -23,717 | -20,710 |
| Capital Expenditure | N/A | -237 | -237 | -237 | -237 |
| Free Cash Flow | -22,535 | -57,909 | -38,619 | -23,954 | -20,947 |